ANTITUMOR AND IMMUNE-BIOLOGICAL ACTIVITY OF A NEW METRONOMIC CHEMOTHERAPY WITH FRACTIONED CISPLATIN AND ORAL ETOPOSIDE COMBINED WITH BEVACIZUMAB (MPEBEV) FOLLOWED BY ERLOTINIB MAINTENANCE IN NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS

被引：0
|
作者：
Correale, Pierpaolo [1 ]
Martellucci, Ignazio [2 ]
Pastina, Pierpaolo [3 ]
Botta, Ciri-No [4 ]
Martino, Elodia [3 ]
Mazza, Daniela [3 ]
Tagliafer-Ri, Pierosandro [4 ]
Pirtoli, Luigi [3 ]
Caraglia, Michele [5 ]
机构：
[1] Siena Univ Hosp, Translat Immunooncol Ctr, Radiotherapy Unit, Siena, Italy
[2] Siena Univ Hosp, Siena, Italy
[3] Univ Siena, Unit Radiotherapy, I-53100 Siena, Italy
[4] Magna Graecia Univ Catanzaro, Med Oncol Unit, Catanzaro, Italy
[5] Univ Naples 2, Naples, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
Metronomic Chemotherapy; Bevacizumab; immunebiological actvity; erlotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-028
引用
收藏
页码：S607 / S608
页数：2
相关论文
共 50 条
  • [41] A Galician Lung Cancer Group phase II study of bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with non-squamous non-small cell lung cancer (NSCLC)
    Leon, L.
    Vazquez, S.
    Gracia, J.
    Casal, J.
    Lazaro, M.
    Firvida, J. L.
    Amenedo, M.
    santome, L.
    Cardona, J. V.
    Macia, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Multicenter phase II study of cisplatin, pemetrexed, plus bevacizumab followed by maintenance pemetrexed plus bevacizumab for patients with advanced or recurrent non-squamous non-small cell lung cancer: MAP study
    Tsutani, Y.
    Miyata, Y.
    Masuda, T.
    Fujitaka, K.
    Doi, M.
    Awaya, Y.
    Kuyama, S.
    Kitaguchi, S.
    Ueda, K.
    Okada, M.
    ANNALS OF ONCOLOGY, 2017, 28 : 137 - 137
  • [43] Randomized, open-label study of pemetrexed/carboplatin followed by maintenance pemetremexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevaciztimab in patients with advanced non-small cell lung cancer (NSCLC) of nonsquamous histology
    Zinner, R.
    Saxman, S.
    Peng, G.
    Ortuzar, W. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous non-small-cell lung cancer who are eligible for bevacizumab and maintenance therapy
    Nakashima, Kazuhisa
    Murakami, Haruyasu
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Endo, Masahiro
    Takahashi, Toshiaki
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (05) : 575 - 578
  • [45] Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study
    Santoro, Armando
    Hillerdal, Gunnar N.
    Hoeffkenc, Gert
    Favaretto, Adolfo
    Carrion, Ramon Perez
    Visseren-Grul, Carla
    Ameryckx, Sophie
    Helsberg, Karin
    Soldatenkova, Victoria
    Bourayou, Nawel
    Sorensen, Jens B.
    LUNG CANCER, 2014, 86 (01) : 47 - 53
  • [46] Randomised phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with OV versus gemcitabine (GEM) and P followed by maintenance with GEM as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients (pts) with squamous (sq) histological type
    Grossi, F.
    Jaskiewicz, P.
    Pichon, E.
    Czyzewicz, G.
    Kowalski, D. M.
    Ciuffreda, L.
    Garcia Gomez, R.
    Caruso, S.
    Bosch Barrera, J.
    Ta Thanh Minh, C.
    Gautier, S.
    Hervieu, H.
    Henriet, S.
    De Castro, G., Jr.
    ANNALS OF ONCOLOGY, 2018, 29
  • [47] The molecular and immune characteristics, antitumor activity of crizotinib in non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping alterations.
    Gan, Jiadi
    Fang, Wenfeng
    Feng, Weineng
    Zhang, Jiexia
    Deng, Huojin
    Zhang, Lei
    Li, Yadan
    Qian, Juanjuan
    Luo, Hongli
    Chen, Yanhui
    Yang, Ying
    Zhang, Henghui
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] A phase II trial of induction Erlotinib followed by chemotherapy with Platinum plus Pemetrexed ± Bevacizumab for EGFR mutation-positive non-squamous non-small cell lung cancer patients.
    Tani, Tetsuo
    Soejima, Kenzo
    Naoki, Katsuhiko
    Arai, Daisuke
    Ishioka, Kouta
    Ohgino, Keiko
    Nishino, Makoto
    Kuroda, Aoi
    Yasuda, Hiroyuki
    Betsuyaku, Tomoko
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
    Zinner, Ralph
    Ross, Helen J.
    Weaver, Robert
    Govindan, Ramaswamy
    Holden, Viran R.
    Chowhan, Naveed Mahfooz
    Beck, J. Thaddeus
    Waterhouse, David Michael
    Modiano, Manuel
    Rao, Vijay Phooshkooru
    Liu, Jingyi
    Koustenis, Andrew
    Melemed, Symantha
    Guba, Susan C.
    Ortuzar, Waldo Feliu
    Desaiah, Durisala
    Spigel, David R.
    Obasaju, Coleman K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [50] Pilot phase II study of neoadjuvant docetaxel (T) and cisplatin (P) followed by adjuvant erlotinib (E) in patients with stage I-III non-small cell lung cancer (NSCLC)
    Gold, Kathryn A.
    Lee, J. Jack
    Rice, David
    Tse, Warner
    Stewart, David
    Wistuba, Ignacio I.
    Herbst, Roy S.
    Lippman, Scott M.
    Hong, Waun K.
    Kim, Edward S.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S784 - S785
12345